Ellevest Inc’s Karyopharm Therapeutics KPTI Stock Holding History

Ellevest Inc’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	–	–	1733
2022 Q2	$0	Sell	1 -1	-50%	-$92	﹤0.01%	1536
2022 Q1	$0	Buy	+2	New	+$249	﹤0.01%	1524

Other funds holding KPTI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Ellevest Inc's KPTI Position: Q3 2022 in Review

Ellevest Inc sold out of Karyopharm Therapeutics (KPTI) in Q3 2022, closing a stake of 1 share.

Ellevest Inc first reported a position in KPTI in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 147 funds tracked by Wall St. Rank hold KPTI as of Q3 2022.

Ellevest Inc reported no remaining Karyopharm Therapeutics position as of Q3 2022 after selling out during the quarter.
Ellevest Inc sold 1 Karyopharm Therapeutics share in Q3 2022.
Ellevest Inc first reported a position in Karyopharm Therapeutics in Q1 2022 and held it in 2 quarters.
Ellevest Inc's Karyopharm Therapeutics position peaked at $0 in Q2 2022.
147 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2022.

Based on Ellevest Inc's 13F filing for Q3 2022, filed 2 Nov 2022.